Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025EDINBURGH, Scotland, Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced an update on the progression of the ACHIEVE UK Trial.As of this week, over hal ...